Shane Schaffer, Cingulate CEO
December 9, 2021 07:15 AM EST
Financing

Cin­gu­late prices a down­sized pub­lic of­fer­ing as IPO par­ty ap­pears to die down

Nicole DeFeudis

Editor

A few months af­ter fil­ing its S-1, Cin­gu­late fi­nal­ly joined the biotech IPO crowd yes­ter­day — but it wasn’t greet­ed with quite the same fan­fare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA lifts hold on En­trada's Duchenne drug af­ter two years

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times